Gov't transfers COVID-19 treatment technology to private companies
Gov't transfers COVID-19 treatment technology to private companies
  • Jung Jun-ho
  • 승인 2020.06.10 11:56
  • 댓글 0
이 기사를 공유합니다

The COVID-19 treatment candidate material discovered by the CEVI Convergence Research Group of the Korea Research Institute of Chemical Technology has been transferred. (From left) Song Chang-woo, director of Korea Institute of Toxicology, Lee Mi-hye, president of Korea Research Institute of Chemical Technology, Kim Yong-joo, CEO of Lego Chem Bioscience, Ryu Wang-sik, director of Institute Pasteur Korea, and Kim Jong-yeol, president of Korea Institute of Oriental Medicine. / Courtesy of Korea Research Institute of Chemical Technology

Candidate drugs for the new coronavirus infection (COVID-19) developed by public research institutes will be transferred to private companies in Korea. It was widely known that the candidate substance was 50 times more effective than Remdesivir in animal testing.

The CEVI Convergence Research Group of the National Institute of Science and Technology (NST) under the Ministry of Science and ICT announced on June 9 that it held an agreement ceremony at the Korea Research Institute of Chemical Technology in Daegu to transfer COVID-19 treatment, vaccine and original technology to private companies. 

The CEVI group is a joint research team created in 2016 by eight government-funded research institutes, including the Korea Institute of Chemical Technology and the Korea Institute of Basic Science.

In the treatment sector, candidate materials that show the ability to kill the Corona 19 virus 50 times higher than Remdesivir, which is being clinical by Gilead Sciences in the U.S., will be transferred to Korean company Lego Chem Bioscience.


A researcher at the Institute Pasteur Korea is observing samples. / Courtesy of Institute Pasteur Korea

The new vaccine candidate material developed by the research team has excellent neutralizing antibody function, which indicates the efficacy of the vaccine. Nonclinical test results showed that the ability to produce neutralized antibodies by corona-19 spike protein, which is being developed as an existing vaccine antigen, was three to five times higher.

Neutralized antibody function is when a vaccine antigen is administered to the body, it combines with antigen in the human body and neutralizes the activity of the antigen. A high level of neutralizing antibody function means that patients with severe diseases as well as mild cases can be prevented from COVID-19.

The convergence research group transfers this technology to HK inno. N. Both agencies plan to conduct joint research for full-time and clinical trials.

"We expect the signing ceremony to speed up the development of COVID-19 vaccines and treatments," said Lee Mi-hye, head of the Korea Chemical Research Institute. "It is a valuable result of our researchers' silent research while all Koreans are keeping distance from their lives due to the influx of Coronavirus into Korea."

삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.

  • #1206, 36-4 Yeouido-dong, Yeongdeungpo-gu, Seoul, Korea(Postal Code 07331)
  • 서울특별시 영등포구 여의도동 36-4 (국제금융로8길 34) / 오륜빌딩 1206호
  • URL: / Editorial Div. 02-578-0434 / 010-2442-9446. Email:
  • Publisher: Monica Younsoo Chung. Chief Editorial Writer: Kim Hyoung-joong. CEO: Lee Kap-soo. Editor: Jung Yeon-jin.
  • Juvenile Protection Manager: Yeon Choul-woong. IT Times Canada: Willow St. Vancouver BC, Canada / 070-7008-0005.
  • Copyright(C) Korea IT Times, Allrights reserved.